Plain-English translation of NCT05824585 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial tested a new drug called in patients with B-cell non-Hodgkin lymphoma that had stopped responding to standard treatments or come back after therapy. Researchers studied how well the medication was tolerated, what side effects occurred, how much of it stayed in the body, and whether it could help shrink cancer tumors.
People with B-cell lymphoma that returns or becomes resistant to standard treatments have limited options and often face poor outcomes. This trial investigated whether this medication could offer a new treatment path for these patients.
Participants received the medication as a monotherapy (meaning it was the only cancer treatment given during this phase). The trial examined safety, tolerability, and how the body processed the medication, as well as whether it showed anti-cancer activity. While specific visit schedules and duration are not detailed in this summary, early-phase trials typically involve regular clinic visits, blood tests, and imaging to monitor both safety and response.
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
United States
Australia